

Supplementary Table 3. Baseline characteristics of acute ischemic stroke patients across included studies

Study	Mean age (yr)	Initial NIHSS	OTT (min)	Baseline SBP, DBP	Female sex (%)	HTN (%)	HLD (%)	DM (%)	AF (%)	Prior AIS/TIA (%)
Ahmed et al. (2009) ¹⁰	70 (60–76)	13 (8–18)	145 (115–170)	151 (138–168), 82 (74–90)	41.5	NA	34.7	17.4	26	12.5
Delgado-Mederos et al. (2008) ¹¹	69.1±13.6	15 (10–19)	194.3±64.7	149±28, 82±16	42.5	53.8	33.8	21.3	NA	NA
Endo et al. (2013) ¹²	70.8±11.6	12 (7–18)	141 (121–165)	NA	34.5	60.5	21.3	18	40.8	NA
Huang et al. (2013) ¹³	62.82±14.25 (mRS 0–1); 68.81±9.85 (mRS 2–6)	12.02±5.26 (mRS 0–1); 15.78±4.98 (mRS 2–6)	142.8±72.6 (mRS 0–1); 154.2±61.8 (mRS 2–6)	135.45±19.36 (mRS 0–1); 148.78±19.39 (mRS 2–6)	54.5 (mRS 0–1); 47.8 (mRS 2–6)	65.45 (mRS 0–1); 71.74 (mRS 2–6)	30.91 (mRS 0–1); 23.91 (mRS 2–6)	9.09 (mRS 0–1); 28.26 (mRS 2–6)	27.27 (mRS 0–1); 39.13 (mRS 2–6)	7.27 (mRS 0–1); 8.7 (mRS 2–6)
Idicula et al. (2008) ¹⁴	63.7±14	13 (median)	NA	156±23, 85±17	34.6	51.2	30.4	6.3	25.4	23.2
Kellert et al. (2012) ¹⁵	74.9±14.6 (sICH); 72.7±12.8 (no sICH)	15.5±12 (sICH); 10.5±9 (no sICH)	NA	NA	80 (sICH); 51.8 (no sICH)	100 (sICH); 80.6 (no sICH)	30 (sICH); 24.5 (no sICH)	30 (sICH); 24.2 (no sICH)	50 (sICH); 32.7 (no sICH)	NA
Kellert et al. (2017) ¹⁶	71 (63–77)	11 (7–16)	145 (120–170)	155 (140–168), NA	40.3	69.7	34.7	11	24.2	13.1
Lindsberg et al. (2003) ¹⁷	63.6	30.3±10.0 (SSS)	NA	NA	46.6	64	NA	13	23	21
Liu et al. (2016) ¹⁸	67.4±13.03	10 (5–16)	232.9±93.85	153.5±22.56, 85.6±14.66	35.8	67.9	40.1	20.8	39.9	17.6
Martins et al. (2016) ¹⁹	73.28±11.50	15.29±7.01	150.25±55.27	NA	46.1	80.4	52.7	24.6	48.9	NA
Menon et al. (2012) ²⁰	69.9±14.7	11 (7–18)	135 (110–160)	NA	49.16	72.2	38.5	24.2	20.6	23.8
Molina et al. (2004) ²¹	67.9±13.6	16 (13–20)	134.1±46.7	NA	52.5	49.6	NA	23.5	26.5	NA
Molina et al. (2009) ²²	63±15 (Cohort 1); 68±15 (Cohort 2); 65±14 (Cohort 3)	10 (4–14) (Cohort 1); 16 (9–21) (Cohort 2); 12 (7–14) (Cohort 3)	139±33 (Cohort 1); 130±32 (Cohort 2); 126±46 (Cohort 3)	150±22 (Cohort 1); 153±32 (Cohort 2); 157±19 (Cohort 3)	34.6	NA	NA	NA	NA	NA
Rusanen et al. (2015) ²³	68.7±13.4	14 (10)	130±38	NA	42	65	NA	16	38	NA
Saqqur et al. (2008) ²⁴	69±13	16 (12–20)	134±32	157±22, NA	47	NA	NA	NA	NA	NA
Tomii et al. (2011) ²⁵	72.7±9	13 (7–18)	NA	158.4±33, 88.1±19.4	26	71	40	20	49	20
Toni et al. (2012) ^{26*}	45 (18–50)	11.3±5.8	145 (117–172)	140 (125–153), 81(73–90)	41.7	27.1	20.6	5.8	4.6	7.1
Tsigoulis et al. (2007) ²⁷	69±14 (recanalized); 68±13 (non-recanalized)	17 (6) (recanalized); 15 (6) (non-recanalized)	142 (43) (recanalized); 145 (48) (non-recanalized)	160±22 (recanalized); 152±23 (non-recanalized)	47 (recanalized); 46 (non-recanalized)	67 (recanalized); 60 (non-recanalized)	NA	37 (recanalized); 20 (non-recanalized)	35 (recanalized); 27 (non-recanalized)	NA

Supplementary Table 3. Continued

Study	Mean age (yr)	Initial NIHSS	OTT (min)	Baseline SBP, DBP	Female sex (%)	HTN (%)	HLD (%)	DM (%)	AF (%)	Prior AIS/TIA (%)
Tsigoulis et al. (2009) ²⁸	71±11 (sICH); 66±15 (no sICH)	12 (10) (sICH); 8 (7) (no sICH)	140 (80) (sICH); 125 (65) (no sICH)	169±29 (sICH); 156±24 (no sICH)	45 (sICH); 44 (no sICH)	68 (sICH); 55 (no sICH)	NA	19 (sICH); 13 (no sICH)	23 (sICH); 11 (no sICH)	NA
Wahlgren et al. (2008) ^{29†}	73 (sICH); 68 (no sICH)	13 (sICH); 12 (no sICH)	140 (no sICH)	150 (no sICH)	42 (sICH); 40 (no sICH)	76 (sICH); 58 (no sICH)	35 (no sICH)	23 (sICH); 16 (no sICH)	36 (sICH); 24 (no sICH)	19 (sICH); 10 (no sICH)
Waltimo et al. (2016) ³⁰	70 (63–78) (sICH); 69 (59–76) (no sICH)	15 (10–21) (sICH); 9 (5–15) (no sICH)	135 (105–230) (sICH); 120 (89–166) (no sICH)	157 (135–171) (sICH); 140 (140–171) (no sICH)	43.5 (sICH); 43.5 (no sICH)	64.2 (sICH); 58.0 (no sICH)	39.4 (sICH); 38.9 (no sICH)	19.3 (sICH); 13.9 (no sICH)	30.3 (sICH); 26.6 (no sICH)	11.0 (sICH); 13.2 (no sICH)
Wu et al. (2017) ³¹	60.04±11.08 (mRS 0–2); 62.71±12.31 (mRS 3–6)	4 (2–7) (mRS 0–2); 10 (4–13) (mRS 3–6)	200 (136–257.5) (mRS 0–2); 207 (157.5–267.25) (mRS 3–6)	147.31±21.72 (mRS 0–2); 149.85±22.61 (mRS 3–6)	24.11 (mRS 0–2); 31.54 (mRS 3–6)	64.82 (mRS 0–2); 73.08 (mRS 3–6)	40.71 (mRS 0–2); 31.54 (mRS 3–6)	32.81 (mRS 0–2); 36.92 (mRS 3–6)	12.65 (mRS 0–2); 14.62 (mRS 3–6)	22.92 (mRS 0–2); 24.62 (mRS 3–6)
Wu et al. (2016) ³²	63.48±11.34	11 (7–16)	169.2±48	148.03±20.95, NA	39.01	59.13	6.47	17.38	17.91	18.44
Yan et al. (2015) ³³	68.81±11.49	12.51±6.62 (recanalized); 12.96±5.39 (non-recanalized)	238.14±96.88 (recanalized); 225.30±92.39 (non-recanalized)	147.98±20.21, 83.01±15.07	32.3	66.7 (recanalized); 67.6 (non-recanalized)	NA	14.9 (recanalized); 18.9 (non-recanalized)	56.3 (recanalized); 47.3 (non-recanalized)	NA
Yong et al. (2005) ^{34†}	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Yong et al. (2008) ^{35§}	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA

Values are presented as median (interquartile range), mean±standard deviation, or number (%).

NIHSS, National Institutes of Health Stroke Scale; OTT, onset-to-treatment; SBP, systolic blood pressure; DBP, diastolic blood pressure; HTN, hypertension; HLD, hyperlipidemia; DM, diabetes mellitus; AF, atrial fibrillation; AIS, acute ischemic stroke; TIA, transient ischemic attack; NA, not available; mRS, modified Rankin Scale; sICH, symptomatic intracranial hemorrhage; SSS, Scandinavian Stroke Scale.

*Results reported for patients 18 to 50 years old; †Demographic variables for sICH/Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST) is presented; ‡50.4% of cohort was treated with intravenous thrombolysis (IVT). Specific demographic details for IVT cohort were not available; §51.3% of cohort was treated with IVT. Specific demographic details for IVT cohort were not available.